Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia

Adam H Dyer; Helen Dolphin; Susan D Shenkin; T Welsh; Pinar Soysal; Hanna-Maria Roitto; Dorota Religa; Sean P. Kennelly; EuGMS Special Interest Group in Dementia

doi:10.1007/s41999-023-00846-2

Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia

Adam H Dyer^*
, Helen Dolphin
, Susan D Shenkin
, T Welsh
, Pinar Soysal
, Hanna-Maria Roitto
, Dorota Religa
, Sean P. Kennelly
, EuGMS Special Interest Group in Dementia

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

7 Citations (Scopus)

Abstract

Alzheimer’s disease [AD] affects 5% of those aged 65–74, rising to one-third of older adults aged 85 and older [1]. “Intellectual impairment” is one of Bernard Isaac’s “geriatric giants” alongside incontinence, immobility and instability (falls), and dementia (the majority of which is caused by AD) is arguably the geriatric syndrome with the greatest impact on quality of life, morbidity and mortality in older adults [2]. AD is a common thread between—and a common risk factor for many of these “geriatric giants” [3, 4]. Following recent breakthroughs in AD diagnostic biomarkers and the potential for disease-modifying therapies (DMT), it is essential that as geriatricians we ensure that the implications of these breakthroughs are considered for all older adults affected by AD. This includes those with mild or early-stage impairments and those with more advanced AD, multiple long-term conditions, polypharmacy and frailty. Critically, any diagnostic and treatment advances must be incorporated alongside gerontologically attuned, person-centred care for older adults with AD.

Original language	English
Pages (from-to)	919-923
Number of pages	5
Journal	European Geriatric Medicine
Volume	14
Early online date	19 Aug 2023
DOIs	https://doi.org/10.1007/s41999-023-00846-2
Publication status	Published - 1 Oct 2023

Bibliographical note

Funding Information:
Members of the EuGMS Specialist Interest Group in Dementia: Burcu Akpinar Soylemez; Mariana Alves; Cansu Atbas; Cafer Balci; Giuseppe Bellelli; Frederic Blanc; Cagatay Cavusoglu; Yaohua Chen; Maria Cherdak; Alessandra Coin; Maria Giovanna Cozza; Mariana Dangiolo; Melanie Dani; Burcu Balam Dogu; Jamin Du; Christina Eleftheriades; Vincenza Frisardi; Lutz Froelich; Seda Guney; Rowan Harold Harwood; Allen Huang; Ruslan Isaev; Saadet Koc Okudur; Victoire Leroy; Maria Margarida Luis; Jurate Macijauskiene; Pavlinka Milosavljevik; Elen Mkhitaryan; Frank Molnar; Enrico Mossello; Peter Passmore; Geeske Peeters; Christian Pozzi; Terence Quinn; Shibley Rahman; Erik Rosendahl; Amrita Roy; Eefje Sizoo; Lee Smith; Thomas Tannou; Verena Tatzer; Suzanne Timmons; Jos Tournoy; Tarja Valimaki; Maja Velevska; Emma Vardy; Nicola Veronese; Mihai Zamfir.

Funding Information:
AHD, SPK and HD are funded by the Meath Foundation, Tallaght University Hospital. AHD has been awarded the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. The ACRC is funded by Legal and General PLC as part of their corporate social responsibility (CSR) programme. The funders had no role in the preparation of this editorial, and the views expressed are those of the authors.

Access to Document

10.1007/s41999-023-00846-2Licence: Unspecified

Handle.net

Persistent link

Cite this

Dyer, A. H., Dolphin, H., Shenkin, S. D., Welsh, T., Soysal, P., Roitto, H.-M., Religa, D., Kennelly, S. P., & Dementia, EMS. S. I. G. I. (2023). Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia. European Geriatric Medicine, 14, 919-923. https://doi.org/10.1007/s41999-023-00846-2

@article{7f35e008402e480dbfcbf15f5100afee,

title = "Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia",

abstract = "Alzheimer{\textquoteright}s disease [AD] affects 5\% of those aged 65–74, rising to one-third of older adults aged 85 and older [1]. “Intellectual impairment” is one of Bernard Isaac{\textquoteright}s “geriatric giants” alongside incontinence, immobility and instability (falls), and dementia (the majority of which is caused by AD) is arguably the geriatric syndrome with the greatest impact on quality of life, morbidity and mortality in older adults [2]. AD is a common thread between—and a common risk factor for many of these “geriatric giants” [3, 4]. Following recent breakthroughs in AD diagnostic biomarkers and the potential for disease-modifying therapies (DMT), it is essential that as geriatricians we ensure that the implications of these breakthroughs are considered for all older adults affected by AD. This includes those with mild or early-stage impairments and those with more advanced AD, multiple long-term conditions, polypharmacy and frailty. Critically, any diagnostic and treatment advances must be incorporated alongside gerontologically attuned, person-centred care for older adults with AD.",

author = "Dyer, \{Adam H\} and Helen Dolphin and Shenkin, \{Susan D\} and T Welsh and Pinar Soysal and Hanna-Maria Roitto and Dorota Religa and Kennelly, \{Sean P.\} and Dementia, \{EuGMS Special Interest Group in\}",

note = "Funding Information: Members of the EuGMS Specialist Interest Group in Dementia: Burcu Akpinar Soylemez; Mariana Alves; Cansu Atbas; Cafer Balci; Giuseppe Bellelli; Frederic Blanc; Cagatay Cavusoglu; Yaohua Chen; Maria Cherdak; Alessandra Coin; Maria Giovanna Cozza; Mariana Dangiolo; Melanie Dani; Burcu Balam Dogu; Jamin Du; Christina Eleftheriades; Vincenza Frisardi; Lutz Froelich; Seda Guney; Rowan Harold Harwood; Allen Huang; Ruslan Isaev; Saadet Koc Okudur; Victoire Leroy; Maria Margarida Luis; Jurate Macijauskiene; Pavlinka Milosavljevik; Elen Mkhitaryan; Frank Molnar; Enrico Mossello; Peter Passmore; Geeske Peeters; Christian Pozzi; Terence Quinn; Shibley Rahman; Erik Rosendahl; Amrita Roy; Eefje Sizoo; Lee Smith; Thomas Tannou; Verena Tatzer; Suzanne Timmons; Jos Tournoy; Tarja Valimaki; Maja Velevska; Emma Vardy; Nicola Veronese; Mihai Zamfir. Funding Information: AHD, SPK and HD are funded by the Meath Foundation, Tallaght University Hospital. AHD has been awarded the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. The ACRC is funded by Legal and General PLC as part of their corporate social responsibility (CSR) programme. The funders had no role in the preparation of this editorial, and the views expressed are those of the authors. ",

year = "2023",

month = oct,

day = "1",

doi = "10.1007/s41999-023-00846-2",

language = "English",

volume = "14",

pages = "919--923",

journal = "European Geriatric Medicine",

issn = "1878-7649",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia

AU - Dyer, Adam H

AU - Dolphin, Helen

AU - Shenkin, Susan D

AU - Welsh, T

AU - Soysal, Pinar

AU - Roitto, Hanna-Maria

AU - Religa, Dorota

AU - Kennelly, Sean P.

AU - Dementia, EuGMS Special Interest Group in

N1 - Funding Information: Members of the EuGMS Specialist Interest Group in Dementia: Burcu Akpinar Soylemez; Mariana Alves; Cansu Atbas; Cafer Balci; Giuseppe Bellelli; Frederic Blanc; Cagatay Cavusoglu; Yaohua Chen; Maria Cherdak; Alessandra Coin; Maria Giovanna Cozza; Mariana Dangiolo; Melanie Dani; Burcu Balam Dogu; Jamin Du; Christina Eleftheriades; Vincenza Frisardi; Lutz Froelich; Seda Guney; Rowan Harold Harwood; Allen Huang; Ruslan Isaev; Saadet Koc Okudur; Victoire Leroy; Maria Margarida Luis; Jurate Macijauskiene; Pavlinka Milosavljevik; Elen Mkhitaryan; Frank Molnar; Enrico Mossello; Peter Passmore; Geeske Peeters; Christian Pozzi; Terence Quinn; Shibley Rahman; Erik Rosendahl; Amrita Roy; Eefje Sizoo; Lee Smith; Thomas Tannou; Verena Tatzer; Suzanne Timmons; Jos Tournoy; Tarja Valimaki; Maja Velevska; Emma Vardy; Nicola Veronese; Mihai Zamfir. Funding Information: AHD, SPK and HD are funded by the Meath Foundation, Tallaght University Hospital. AHD has been awarded the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. The ACRC is funded by Legal and General PLC as part of their corporate social responsibility (CSR) programme. The funders had no role in the preparation of this editorial, and the views expressed are those of the authors.

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Alzheimer’s disease [AD] affects 5% of those aged 65–74, rising to one-third of older adults aged 85 and older [1]. “Intellectual impairment” is one of Bernard Isaac’s “geriatric giants” alongside incontinence, immobility and instability (falls), and dementia (the majority of which is caused by AD) is arguably the geriatric syndrome with the greatest impact on quality of life, morbidity and mortality in older adults [2]. AD is a common thread between—and a common risk factor for many of these “geriatric giants” [3, 4]. Following recent breakthroughs in AD diagnostic biomarkers and the potential for disease-modifying therapies (DMT), it is essential that as geriatricians we ensure that the implications of these breakthroughs are considered for all older adults affected by AD. This includes those with mild or early-stage impairments and those with more advanced AD, multiple long-term conditions, polypharmacy and frailty. Critically, any diagnostic and treatment advances must be incorporated alongside gerontologically attuned, person-centred care for older adults with AD.

AB - Alzheimer’s disease [AD] affects 5% of those aged 65–74, rising to one-third of older adults aged 85 and older [1]. “Intellectual impairment” is one of Bernard Isaac’s “geriatric giants” alongside incontinence, immobility and instability (falls), and dementia (the majority of which is caused by AD) is arguably the geriatric syndrome with the greatest impact on quality of life, morbidity and mortality in older adults [2]. AD is a common thread between—and a common risk factor for many of these “geriatric giants” [3, 4]. Following recent breakthroughs in AD diagnostic biomarkers and the potential for disease-modifying therapies (DMT), it is essential that as geriatricians we ensure that the implications of these breakthroughs are considered for all older adults affected by AD. This includes those with mild or early-stage impairments and those with more advanced AD, multiple long-term conditions, polypharmacy and frailty. Critically, any diagnostic and treatment advances must be incorporated alongside gerontologically attuned, person-centred care for older adults with AD.

UR - http://europepmc.org/abstract/med/37597074

U2 - 10.1007/s41999-023-00846-2

DO - 10.1007/s41999-023-00846-2

M3 - Article (Academic Journal)

C2 - 37597074

SN - 1878-7649

VL - 14

SP - 919

EP - 923

JO - European Geriatric Medicine

JF - European Geriatric Medicine

ER -

Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia

Abstract

Bibliographical note

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this